A Phase II Multicenter, Single Arm Study of Oral BGJ398 in Adult Patients with Advanced or Metastatic Cholangiocarcinoma with FGFR2 Gene Fusions or Other FGFR Genetic Alterations who Failed or Are Intolerant to Platinum-Based Chemotherapy (CBGJ398X2204)
MD Anderson Study Status
This is a multi-center, open label, single arm phase II study evaluating BGJ398 anti-tumor activity in advanced or metastatic cholangiocarcinoma patients with Fibroblast Growth Factor receptor (FGFR) genetic alterations.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Advanced Cholangiocarcinoma, FGFR2 Gene Mutation
Gastrointestinal Medical Oncology
For general questions about clinical trials:
Due to our response to COVID-19, all blood donations at MD Anderson
Blood Donor Center locations are being held by appointment only.